Discuva

BIA responds to Jim O’Neill’s review on antimicrobial resistance

Monday, June 22, 2015

The U.K. Bioindustry Association (BIA) has submitted its initial response to Jim O’Neill’s review on antimicrobial resistance (AMR), focusing on his interim report Securing new drugs for future generations: The antibiotics pipeline, published in May. Steve Bates, CEO of the BIA, put forward the case that any new economic model should be based on an informed stewardship not restrictive stewardship approach.

[Read More]

Roche, Discuva collaborate on new antibiotics

Monday, March 3, 2014

Roche and Discuva have entered into a worldwide collaboration and license agreement for the discovery and development of new antibiotics to treat life-threatening infections caused by multi-drug resistant Gram-negative bacteria using Discuva’s proprietary SATINtechnology platform.

[Read More]